Development and validation of competition binding assays for affinity to the extracellular matrix receptors, αvβ3 and αIIbβ3 integrin

Analytical Biochemistry

Volumn 423, Issue 1, 2012, Pages 70-77

  Szabo, Alexander M ^a   Howell, Nicholas R ^a   Pellegrini, Paul ^a   Greguric, Ivan ^a   Katsifis, Andrew ^a  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Biotinylated ligand; Competitive affinity assay; Echistatin; GPIIb IIIa; Radiolabeled ligand

Indexed keywords

PROTEINS;

ACTIVATED CONFORMATION; AFFINITY ASSAYS; ECHISTATIN; EXTRACELLULAR MATRICES; GPIIB/IIIA; INTER-ASSAY VARIABILITY; PHYSIOLOGICAL PROCESS; RECEPTOR-LIGAND INTERACTIONS;

LIGANDS;

ALPHA2BBETA3 INTEGRIN RECEPTOR; ANTIBODY; ARGINYLGLYCYLASPARTIC ACID; ECHISTATIN; INTEGRIN RECEPTOR; LIGAND; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; ASSAY; BINDING COMPETITION; CONFORMATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MOLECULAR MODEL; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; SOLID; VALIDATION PROCESS;

EID: 84857345852     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2011.12.046     Document Type: Article

References (45)

1. M. Barczyk, S. Carracedo, D. Gullberg, Integrins, Cell Tissue Res. 339 (2010) 269-280.
2. J.D. Humphries, A. Byron, M.J. Humphries, Integrin ligands at a glance, J. Cell Sci. 119 (2006) 3901-3903. (Pubitemid 44650863)
3. J. Folkman, Angiogenesis: an organizing principle for drug discovery?, Nat Rev. Drug Discov. 6 (2007) 273-286. (Pubitemid 46505878)
4. A. Bagri, H. Kouros-Mehr, K.G. Leong, G.D. Plowman, Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale, Trends Mol. Med. 16 (2010) 122-132.
5. 3 expression, Cancer Metastasis Rev. 27 (2008) 631-644.
6. I. Dijkgraaf, O.C. Boerman, Radionuclide imaging of tumor angiogenesis, Cancer Biother. Radiopharm. 24 (2009) 637-647.
7. 3integrin expression in vivo, Acc. Chem. Res. 42 (2009) 969-980.
8. v integrins during angiogenesis, Mol. Med. 4 (1998) 741-750.
9. 3for angiogenesis, Science 264 (1994) 569-571.
10. 3 integrins in osteoclast function, J. Bone Mineral Metab. 25 (2007) 337-344.
11. 3, J. Clin. Invest. 115 (2005) 3363-3369.
12. V.R. Deutsch, A. Tomer, Megakaryocyte development and platelet production, Br. J. Haematol. 134 (2006) 453-466. (Pubitemid 44141711)
13. I.P. Casserly, E.J. Topol, Glycoprotein IIb/IIIa antagonists - from bench to practice, Cell. Mol. Life Sci. 59 (2002) 478-500. (Pubitemid 34267388)
14. 3) odyssey: a technologydriven saga of a receptor with twists, turns, and even a bend, Blood 112 (2008) 3011-3025.
15. 3antagonists inhibit insulin-like growth factor-I-stimulated smooth muscle cell migration and replication, Endocrinology 140 (1999) 4616-4621.
16. M.M. Mehrotra, J.A. Heath, M.S. Smyth, A. Pandey, J.W. Rose, J.M. Seroogy, D.L. Volkots, L. Nannizzi-Alaimo, G.L. Park, J.L. Lambing, S.J. Hollenbach, R.M. Scarborough, Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists, J. Med. Chem. 47 (2004) 2037-2061. (Pubitemid 38453920)
17. K. Suzuki, K. Sato, M. Kamohara, S. Kaku, T. Kawasaki, S. Yano, Y. Iizumi, Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties, Biol. Pharm. Bull. 25 (2002) 1006-1012. (Pubitemid 39663222)
18. 3) inhibitors in plasma: application as an ex vivo pharmacodynamic model, J. Biochem. Biophys. Methods 65 (2005) 107-120.
19. 3 receptor, J. Pharmacol. Exp. Ther. 283 (1997) 843-853.
20. 3 integrin reconstituted into planar lipid bilayers, J. Biol. Chem. 268 (1993) 6800-6808.
21. 3 and its ligand, J. Biol. Chem. 266 (1991) 19543-19550.
22. H. Motulsky, R. Neubig, Analyzing radioligand binding data, Curr. Protoc. Neurosci. (2002). unit 7.5.
23. R.A. Bednar, S.L. Gaul, T.G. Hamill, M.S. Egbertson, J.A. Shafer, G.D. Hartman, R.J. Gould, B. Bednar, Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets, J. Pharmacol. Exp. Ther. 285 (1998) 1317-1326. (Pubitemid 28277935)
24. 125I]L-775,219, J. Labelled Compd. Radiopharm. 44 (2001) 55-59.
25. 3: evidence for a common binding site for cyclic arginyl-glycinyl- aspartic acid peptides and nonpeptides, J. Pharmacol. Exp. Ther. 285 (1998) 228-235.
26. 3 antagonist, J. Med. Chem. 43 (2000) 3736-3745.
27. P.A. Pellegrini, The Synthesis and Biological Evaluation of Integrin Receptor Targeting Molecules as Potential Radiopharmaceuticals, University of Western Sydney, Campbelltown, Australia, 2008.
28. H. Motulsky, A. Christopoulos, Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting, Oxford University Press, Oxford, UK, 2004.
29. 3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families, Haematologica 94 (2009) 663-669.
30. 3 expression with F-18-FRGD2, J. Nucl. Med. 47 (2006) 113-121.
31. D.B. Bylund, M.L. Toews, Radioligand binding methods: practical guide and tips, Am. J. Physiol. 265 (1993) L421-L429.
32. G. Thibault, Sodium dodecyl sulfate-stable complexes of echistatin and RGD-dependent integrins: a novel approach to study integrins, Mol. Pharmacol. 58 (2000) 1137-1145.
33. M. Yamamoto, J.E. Fisher, M. Gentile, J.G. Seedor, C.T. Leu, S.B. Rodan, G.A. Rodan, The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats, Endocrinology 139 (1998) 1411-1419. (Pubitemid 28510163)
34. 3 integrins, Biochem. J. 317 (1996) 817-825.
35. 3H]SK&F-107260 binding assay, Mol. Pharmacol. 50 (1996) 529-537.
36. E.I.B. Peerschke, Maintenance of GPIIb-IIIa avidity supporting "irreversible"fibrinogen binding is energy-dependent, J. Lab. Clin. Med. 134 (1999) 398-404. (Pubitemid 29490160)
37. 3integrin, J. Nucl. Med. 51 (2010) 251-258.
38. J.E. Sprague, H. Kitaura, W. Zou, Y.P. Ye, S. Achilefu, K.N. Weilbaecher, S.L. Teitelbaum, C.J. Anderson, Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide, J. Nucl. Med. 48 (2007) 311-318. (Pubitemid 47555359)
39. 5 integrin binders embedding 4-aminoproline residues, J. Med. Chem. 51 (2008) 1771-1782.
40. C.C. Kumar, H.M. Nie, L. Armstrong, R.M. Zhang, S. Vijay-Kumar, A. Tsarbopoulos, Chloramine T-induced structural and biochemical changes in echistatin, FEBS Lett. 429 (1998) 239-248. (Pubitemid 28300368)
41. C. Altomare, M. de Candia, F. Liantonio, A. Carotti, R. De Cristofaro, Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation, J. Med. Chem. 52 (2009) 1018-1028.
42. D. Kikelj, J. Ilas, Z. Jakopin, T. Borstnar, M. Stegnar, 3,4-Dihydro-2H-1,4- benzoxazine derivatives combining thrombin inhibitory and glycoprotein IIb/ IIIa receptor antagonistic activity as a novel class of antithrombotic compounds with dual function, J. Med. Chem. 51 (2008) 5617-5629.
43. 3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers, J. Med. Chem. 52 (2009) 7029-7043.
44. 3:ligand interactions are linked to bindingsite remodeling, Protein Sci. 15 (2006) 1893-1906.
45. K. Yoshimura, T. Miyazaki, N. Furuyama, Z.I. Terashita, Y. Fujisawa, Binding properties of fibrinogen receptor GPIIb-IIIa purified from human erythroleukemia cells, Biochem. Mol. Med. 56 (1995) 166-171. (Pubitemid 26029439)